Polyarteritis Nodosa: ['A necrotizing vasculitis that affects medium-sized arteries, it is usually idiopathic, and may be triggered by viral infections (Hepatitis B, also others). A multisystem disease, it most commonly affects skin (nodules, livedo reticularis) and peripheral nerves; higher morbidity is associated with gastrointestinal, central nervous system, cardiac, and/or other organ involvement. Anti-neutrophil cytoplasmic antibodies (ANCA) are typically negative. [ NCI ]']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
259 |
4. Check minimum number of eventsNone |
259 |
5. Include endpointsNone |
259 |
6. Filter based on genotype QC (FinnGen only) |
251 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M30
- Name in latin
- Polyarteritis nodosa
Similar endpoints
↥List of similar endpoints to
Polyarteritis nodosa
based on the number of shared cases.
Similar with more cases:
- Polyarteritis nodosa and related conditions
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2412 | 1441 | 939 |
| Only index persons | 1633 | 982 | 651 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.03 | 0.04 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 66.80 | 70.69 | 60.69 |
| Only index persons | 61.28 | 64.65 | 56.21 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 251 | 143 | 108 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 60.11 | 59.46 | 60.98 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 259
- Matched controls
- 2590
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M30.0
ICD-10 Finland
Polyarteritis nodosa
+∞
260.5
204
*
L04AX01
ATC
azathioprine; systemic
23.0
83.8
66
38
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
10.8
67.9
91
124
N08.5*M30.0
ICD-10 Finland
Glomerular disorders in polyarteritis nodosa
+∞
38.5
36
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.2
33.1
49
72
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
9.1
31.6
42
54
L04AA06
ATC
mycophenolic acid; systemic
47.6
30.9
37
9
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.2
28.9
148
626
H02AB06
ATC
prednisolone; systemic
4.4
28.6
176
845
M31.3
ICD-10 Finland
Wegener granulomatosis
+∞
26.5
25
*
M05BA04
ATC
alendronic acid; oral
5.5
26.4
60
135
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.9
25.7
44
75
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.9
25.1
68
177
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.2
25.0
60
141
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.0
24.2
62
154
L04AX03
ATC
methotrexate; systemic
5.6
23.1
50
107
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
83.9
21.0
23
*
M30.8
ICD-10 Finland
Other conditions related to polyarteritis nodosa
+∞
20.1
19
*
N08.5*M31.3
ICD-10 Finland
Glomerular disorders in Wegener's granulomatosis
+∞
19.0
18
*
M31.8
ICD-10 Finland
Other specified necrotizing vasculopathies
+∞
19.0
18
*
C03CA01
ATC
furosemide; systemic
3.2
19.0
134
650
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
22.9
17.7
25
12
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
21.1
17.2
25
13
P01BA02
ATC
hydroxychloroquine; oral
5.2
17.2
39
86
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
7.1
17.0
27
42
L01AA01
ATC
cyclophosphamide; systemic
68.0
17.0
19
*
Z49.1
ICD-10 Finland
Extracorporeal dialysis
37.9
16.9
21
6
4460A
ICD-9 Finland
Polyarteritis nodosa and allied conditions, Polyarteritis nodosa[POLYARTERITIS NODOSA (CLASSICA)]
+∞
16.8
16
*
F02.89*M30.0
ICD-10 Finland
Dementia in polyarteritis nodosa
+∞
16.8
16
*
N08.5
ICD-10 Finland
Glomerular disorders in systemic connective tissue disorders
+∞
16.8
16
*
H02AB04
ATC
methylprednisolone; systemic
3.7
16.0
61
200
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.9
15.9
149
823
M31.7
ICD-10 Finland
Microscopic polyangiitis
+∞
15.8
15
*
A11CC03
ATC
alfacalcidol; systemic
16.1
15.7
25
17
Z94.0
ICD-10 Finland
Kidney transplant status
169.8
15.7
16
*
N03AX16
ATC
[U] pregabalin
3.1
15.3
86
358
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
5.7
14.3
28
54
A12AA04
ATC
calcium carbonate; oral
25.5
14.0
19
8
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
5.4
13.9
29
59
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
7.0
13.9
22
34
A10AC01
ATC
insulin (human); parenteral
4.0
13.8
44
127
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.9
13.7
32
72
J01MA12
ATC
levofloxacin; systemic
3.1
13.7
73
293
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
+∞
13.7
13
*
44600
ICD-8 Finland
Polyarteritis nodosa and allied conditions, Polyarteritis nodosa
+∞
13.7
13
*
M31.9
ICD-10 Finland
Necrotizing vasculopathy, unspecified
+∞
13.7
13
*
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
22.6
13.5
19
9
R50.9
ICD-10 Finland
Fever, unspecified
3.3
13.0
58
209
N08.5*M31.7
ICD-10 Finland
Glomerular disease states in microscopic polyangiitis
+∞
12.6
12
*
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
+∞
12.6
12
*
N085, M318,
ICD-10 Finland
+∞
12.6
12
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.2
12.4
35
92
TK800
NOMESCO Finland
Hemodialysis
13.3
12.4
21
17
127
Kela drug reimbursment
Transplant complication
22.6
12.2
17
8
H02AB07
ATC
prednisone; oral
3.2
11.6
53
193
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
+∞
11.5
11
*
A02BC01
ATC
omeprazole; systemic
2.5
11.2
95
480
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
5.5
11.0
22
43
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.8
11.0
66
280
D69.0
ICD-10 Finland
Allergic purpura
62.6
10.7
12
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
4.4
10.5
28
70
L04AD01
ATC
ciclosporin; systemic
12.8
10.5
18
15
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
+∞
10.5
10
*
M30.3
ICD-10 Finland
Mucocutaneous lymph node syndrome [Kawasaki]
+∞
10.5
10
*
S97
ICPC
Chronic ulcer skin
4.0
10.5
32
89
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.5
10.3
93
480
D64.9
ICD-10 Finland
Anaemia, unspecified
3.2
10.1
44
155
M31.5
ICD-10 Finland
Giant cell arteritis with polymyalgia rheumatica
57.2
9.7
11
*
N30.0
ICD-10 Finland
Acute cystitis
2.9
9.7
54
219
J01FF01
ATC
clindamycin; systemic
2.4
9.6
87
448
N17.9
ICD-10 Finland
Acute renal failure, unspecified
5.0
9.5
21
45
J01MA02
ATC
ciprofloxacin; systemic
2.3
9.4
120
713
N08.5*M32.1
ICD-10 Finland
Glomerular disorders in systemic lupus erythematosus
+∞
9.4
9
*
N08.5*M31.0
ICD-10 Finland
Glomerular disorders in Goodpasture's syndrome
+∞
9.4
9
*
ZX120
NOMESCO Finland
Intravenous
3.3
9.4
39
133
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
9.4
92
490
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.1
9.0
26
69
N18.0
ICD-10 Finland
End-stage renal disease
19.5
9.0
13
7
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
4.3
9.0
24
60
B03XA02
ATC
darbepoetin alfa; parenteral
11.3
8.9
16
15
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
4.2
8.8
24
61
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
4.7
8.8
21
48
ZXD05
NOMESCO Finland
Urgent procedure
2.3
8.8
95
525
L04AD02
ATC
tacrolimus; systemic
51.8
8.7
10
*
137
Kela drug reimbursment
Uraemia requiring dialysis
51.8
8.7
10
*
Z49.0
ICD-10 Finland
Preparatory care for dialysis
28.6
8.6
11
*
A12BA01
ATC
potassium chloride; oral
3.7
8.5
28
82
I77.6
ICD-10 Finland
Arteritis, unspecified
93.0
8.5
9
*
A12AA12
ATC
[U] calcium acetate
93.0
8.5
9
*
TQW80
NOMESCO Finland
Local dermatologic skincare
9.0
8.4
17
20
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.3
8.4
34
114
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
+∞
8.4
8
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
8.4
8
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.6
8.2
54
238
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
17.9
8.2
12
7
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
4.9
8.0
18
39
Z2446
NOMESCO Finland
Social worker
3.6
7.9
27
81
WX892
NOMESCO Finland
Monitored bed care
3.4
7.8
30
97
M13.9
ICD-10 Finland
Arthritis, unspecified
3.6
7.8
27
82
TK810
NOMESCO Finland
Hemofiltration
46.4
7.8
9
*
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.6
7.7
51
224
L04AA01
ATC
[U] ciclosporin
12.4
7.7
13
11
M35.3
ICD-10 Finland
Polymyalgia rheumatica
9.3
7.7
15
17
A10AB05
ATC
insulin aspart; parenteral
3.1
7.7
33
115
TPH04
NOMESCO Finland
Cathetrisation of vein
2.3
7.5
65
324
SPAT1255
SPAT
Intravenous administration of medicine
3.8
7.3
23
65
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.3
7.3
29
96
J01MA06
ATC
norfloxacin; oral
2.5
7.2
50
225
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
7.2
75
404
A46
ICD-10 Finland
Erysipelas
2.5
7.1
49
219
TGC00
NOMESCO Finland
Bronchial lavation
6.2
7.1
18
31
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.3
7.0
60
297
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.9
7.0
35
133
XW000
NOMESCO Finland
Bone marrow biopsy
4.3
6.9
18
44
N18.8
ICD-10 Finland
Other chronic renal failure
7.5
6.8
15
21
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
17.2
6.8
10
6
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
6.7
62
316
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
23.2
6.7
9
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.4
6.6
49
227
L01BA01
ATC
methotrexate; systemic
5.6
6.6
18
34
L88
ICPC
Rheumatoid/seropositive arthritis
6.0
6.6
17
30
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
6.0
6.6
17
30
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
6.0
6.6
17
30
JN4AD
NOMESCO Finland
Body CT examination
2.9
6.5
33
126
AA1AD
NOMESCO Finland
CT of head and brain
2.1
6.5
79
449
N02AX02
ATC
tramadol; systemic, rectal
2.0
6.5
117
766
PAW37
NOMESCO Finland
Biopsy of temporal artery
71.5
6.5
7
*
L52
ICD-10 Finland
Erythema nodosum
14.8
6.4
10
7
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
6.4
39
164
A02BC05
ATC
esomeprazole; systemic
2.0
6.3
114
744
C08CA01
ATC
amlodipine; oral
2.0
6.3
112
727
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
18.6
6.3
9
5
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
18.6
6.3
9
5
N08.5*M31.1
ICD-10 Finland
Glomerular disorders in thrombotic thrombocytopenic purpura
+∞
6.3
6
*
JN6JR
NOMESCO Finland
Extensive PET-CT of whole body metabolism (crown to foot)
+∞
6.3
6
*
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
+∞
6.3
6
*
L88
ICD-10 Finland
Pyoderma gangrenosum
+∞
6.3
6
*
R02
ICPC
Shortness of breath/dyspnoea
2.6
6.2
39
167
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
4.3
6.2
16
39
A07EC01
ATC
sulfasalazine; oral, rectal
3.2
6.1
24
79
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
48
43
13.47
47.16
4.0
1.1
9.09
—
iu/ml
—
8
0
26
29
9.85
21.56
7.4
7.4
471.75
178.40
iu/ml
—
8
5
51
127
4.76
19.61
2.1
2.9
64.40
66.06
g/l
0.64
45
113
32
52
6.88
19.42
2.7
1.3
—
—
—
0
0
51
137
4.39
17.75
7.5
3.4
124.71
79.85
ng/l
1.62
43
122
156
946
2.63
12.87
14.4
6.7
1.20
1.21
mmol/l
1.01
133
799
22
37
6.41
12.81
1.5
1.2
4.16
2.46
u/ml
—
5
5
67
268
3.02
12.52
4.5
2.1
19.09
22.16
%
1.03
57
224
135
785
2.50
11.87
3.3
2.2
80.26
74.77
nmol/l
1.50
130
691
23
44
5.64
11.77
1.9
5.3
48.91
233.18
mg/l
0.65
18
34
23
44
5.64
11.77
1.9
5.3
33.26
34.34
mg/l
0.05
18
35
124
714
2.41
10.88
5.9
2.9
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
23
49
5.05
10.46
3.9
2.1
0.31
0.34
u/ml
0.13
15
24
23
50
4.95
10.22
1.8
1.4
0.20
0.04
iu/ml
—
5
9
17
15
12.04
9.71
1.5
1.1
—
—
—
0
0
28
77
3.96
9.28
1.4
2.2
36.13
38.85
u/l
0.32
23
68
40
147
3.04
8.49
1.5
1.5
—
—
—
0
0
67
323
2.45
8.40
2.3
1.8
—
—
—
0
0
34
115
3.25
8.29
5.7
3.1
1.86
1.45
mmol/l
0.17
28
86
18
25
7.65
8.11
1.4
1.2
282.73
180.00
u/ml
0.61
11
13
75
386
2.33
8.09
1.9
1.6
1310.82
1194.67
nmol/l
0.45
64
291
88
489
2.21
7.88
3.1
2.0
3.21
3.19
mg/l
0.03
82
417
18
28
6.83
7.56
1.4
1.2
—
—
—
0
0
100
596
2.10
7.41
3.4
2.1
157.11
238.79
u/l
1.09
95
559
16
23
7.34
7.11
1.4
1.0
10.40
1.33
u/ml
—
5
9
18
31
6.16
7.05
4.8
2.8
60.22
60.23
%
0.00
18
31
96
575
2.06
6.93
6.7
3.8
23.84
9.56
mg/mmol
1.05
70
360
17
28
6.42
6.90
4.3
2.3
4.41
5.05
e9/l
0.41
17
28
22
63
3.72
6.88
2.7
2.6
—
—
—
0
0
16
27
6.24
6.41
1.5
1.3
134.20
103.40
u/ml
—
5
5
60
309
2.23
6.33
1.5
1.2
33.14
32.38
iu/ml
0.02
23
106
17
32
5.61
6.27
1.2
1.3
—
—
—
0
0
40
173
2.55
6.22
8.9
3.6
5.91
5.65
kpa
1.18
40
168
84
496
2.03
6.20
3.4
2.6
1945.79
9351.26
umol/l
1.63
73
423
58
297
2.23
6.19
1.3
1.2
19.77
11.80
u/ml
0.28
25
110
15
25
6.30
6.09
1.5
1.1
3.00
2.30
u/ml
—
6
10
13
18
7.54
6.00
1.8
3.3
—
—
—
0
0
91
563
1.95
5.82
5.5
3.0
0.35
0.48
e6/l
0.33
80
427
12
16
7.80
5.70
1.0
1.0
—
—
—
0
0
16
42
3.99
5.63
1.3
1.4
—
—
—
0
0
9
7
13.26
5.62
1.1
1.0
—
—
—
0
0
27
102
2.84
5.44
1.3
1.3
—
38.64
—
0
7
71
414
1.98
5.33
2.0
1.8
0.93
1.46
mg/l
1.80
60
333
5
0
+∞
5.22
3.2
0.0
—
—
—
0
0
133
954
1.81
5.21
15.2
13.5
1.23
1.25
inr
0.08
52
289
29
117
2.67
5.17
2.2
2.4
—
14.64
—
0
5
102
682
1.82
4.99
3.9
3.2
2.30
2.36
mmol/l
2.48
92
594
95
629
1.81
4.75
4.3
3.1
34.64
32.82
u/l
0.11
88
593
16
48
3.49
4.69
1.1
1.3
—
—
—
0
0
8
8
10.27
4.55
1.3
1.0
76.00
122.55
iu/ml
—
8
8
16
49
3.41
4.55
1.4
1.4
—
—
—
0
0
43
220
2.14
4.55
2.3
1.7
—
—
—
0
0
16
50
3.34
4.41
1.4
1.4
—
—
—
0
0
18
61
3.10
4.38
3.4
2.3
—
—
—
0
0
43
224
2.10
4.34
2.4
1.8
—
—
—
0
0
89
597
1.75
4.17
3.0
2.5
49.54
62.87
u/l
0.99
81
559
152
1180
1.70
4.15
9.3
4.9
6.95
6.73
mmol/l
0.53
146
1093
9
14
6.61
4.02
1.1
1.2
—
—
—
0
0
9
14
6.61
4.02
1.1
1.2
—
—
—
0
0
81
534
1.75
4.01
6.2
3.9
0.00
0.00
estimate
-0.00
36
184
17
59
3.01
3.98
1.4
1.2
—
—
—
0
0
19
71
2.81
3.92
1.7
1.7
—
—
—
0
0
20
77
2.73
3.91
1.9
1.8
—
—
—
0
0
9
15
6.17
3.85
1.1
1.2
—
—
—
0
0
9
15
6.17
3.85
1.1
1.2
—
—
—
0
0
9
15
6.17
3.85
1.1
1.2
—
—
—
0
0
9
15
6.17
3.85
2.2
1.6
—
—
—
0
0
9
15
6.17
3.85
2.6
1.9
—
—
—
0
0
60
367
1.83
3.80
4.4
3.7
870.86
174.51
ng/l
0.77
50
301
129
978
1.64
3.71
6.0
3.7
0.00
0.00
estimate
-0.00
35
186
8
12
6.84
3.70
2.4
2.4
—
—
—
0
0
127
965
1.62
3.58
8.2
5.0
0.00
0.00
estimate
-0.00
37
193
126
962
1.60
3.44
6.1
3.7
0.00
0.00
estimate
0.50
37
204
163
1325
1.62
3.42
7.9
4.4
11196.11
2205.47
e6/l
—
9
32
118
898
1.58
3.20
3.6
2.6
—
—
—
0
0
23
106
2.28
3.13
5.7
6.0
24.52
24.29
mmol/l
0.12
23
106
38
213
1.92
3.13
3.6
3.3
—
—
—
0
0
8
16
5.12
3.07
1.0
1.1
—
—
—
0
0
7
12
5.96
3.04
1.1
1.3
—
—
—
0
0
5
5
10.16
2.99
2.2
2.4
—
—
—
0
0
12
37
3.35
2.97
2.6
3.1
4.95
4.97
kpa
0.04
12
37
11
32
3.54
2.93
1.5
1.5
—
—
—
0
0
11
32
3.54
2.93
1.5
1.5
—
—
—
0
0
10
27
3.81
2.91
1.3
1.4
—
—
—
0
0
12
38
3.26
2.89
1.6
1.4
—
—
—
0
0
7
13
5.50
2.89
3.4
2.7
83.86
96.23
%
—
7
13
85
612
1.58
2.87
3.9
3.1
3308.69
1518.56
ng/l
0.52
77
522
13
47
2.86
2.86
2.0
1.3
—
—
—
0
0
11
34
3.33
2.76
1.5
1.4
—
—
—
0
0
106
809
1.53
2.74
2.4
2.0
91.77
93.81
pmol/l
0.20
69
413
71
495
1.60
2.73
1.8
1.5
17.75
20.61
nmol/l
1.23
63
419
28
149
1.99
2.68
6.2
2.6
59.53
60.87
ml/min/173m2
0.06
15
63
11
35
3.24
2.68
1.3
1.5
—
—
—
0
0
5
7
7.25
2.56
1.4
1.6
—
—
—
0
0
6
11
5.55
2.55
1.2
1.5
—
—
—
0
0
6
11
5.55
2.55
1.2
1.5
—
—
—
0
0
7
16
4.46
2.49
1.4
1.8
—
—
—
0
0
7
16
4.46
2.49
1.4
1.8
—
—
—
0
0
7
16
4.46
2.49
1.4
1.8
—
—
—
0
0
14
58
2.49
2.41
1.5
1.2
—
—
—
0
0
11
39
2.90
2.37
1.5
1.5
—
—
—
0
0
8
23
3.55
2.29
1.8
1.3
—
—
—
0
0
8
23
3.55
2.29
1.8
1.3
—
—
—
0
0
7
18
3.97
2.27
1.0
1.2
—
—
—
0
0
7
18
3.97
2.27
1.0
1.9
—
—
—
0
0
14
60
2.41
2.26
2.0
1.4
—
—
—
0
0
6
166
0.35
2.24
1.7
1.6
—
—
—
0
0
7
19
3.76
2.16
1.0
1.2
—
—
—
0
0
7
19
3.76
2.16
3.3
2.2
—
—
—
0
0
9
31
2.97
2.09
1.3
1.3
—
—
—
0
0
9
31
2.97
2.09
1.7
1.5
—
—
—
0
0
5
10
5.07
2.08
1.0
1.0
—
—
—
0
0
7
20
3.57
2.07
1.0
1.8
—
—
—
0
0
7
20
3.57
2.07
1.1
1.3
—
—
—
0
0
38
243
1.66
2.05
11.8
6.9
102.95
104.10
mmol/l
1.06
38
243
8
26
3.14
2.03
1.4
1.0
—
—
—
0
0
5
11
4.61
1.95
1.2
1.5
—
—
—
0
0
5
11
4.61
1.95
1.0
1.0
—
—
—
0
0
101
809
1.41
1.89
6.8
3.9
39.57
45.51
ng/l
0.23
76
569
61
445
1.49
1.87
3.7
2.3
—
—
—
0
0
5
12
4.23
1.83
1.2
1.4
—
—
—
0
0
57
417
1.47
1.72
1.2
1.2
0.72
1.53
u/ml
0.82
13
110
5
13
3.90
1.72
1.4
1.2
—
—
—
0
0
5
13
3.90
1.72
1.2
1.2
40.60
50.46
u/l
—
5
13
10
41
2.50
1.66
1.1
1.4
—
—
—
0
0
7
25
2.85
1.66
1.3
1.3
—
—
—
0
0
5
14
3.62
1.62
1.2
1.1
85.00
71.43
umol/l
—
5
14
10
44
2.32
1.57
1.0
1.1
—
—
—
0
0
19
108
1.82
1.55
1.8
1.4
—
—
—
0
0
45
321
1.49
1.54
4.6
2.7
1.44
2.35
e6/l
0.64
26
175
5
15
3.38
1.53
1.2
1.5
—
—
—
0
0
5
15
3.38
1.53
1.0
1.1
—
—
—
0
0
5
15
3.38
1.53
1.2
1.3
—
—
—
0
0
9
40
2.29
1.41
1.6
1.3
—
—
—
0
0
9
40
2.29
1.41
1.6
1.3
—
—
—
0
0
210
1947
1.42
1.38
35.4
14.1
26.39
23.51
mg/l
0.58
191
1529
93
767
1.33
1.38
6.5
3.8
—
—
—
0
0
46
339
1.43
1.34
4.5
2.6
0.97
0.98
e6/l
0.01
27
191
5
18
2.81
1.29
1.2
1.3
—
—
—
0
0
6
25
2.43
1.25
3.0
2.4
—
35.72
—
0
6
10
51
2.00
1.12
1.7
1.3
—
—
—
0
0
39
289
1.41
1.12
1.6
1.4
—
—
—
0
0
5
21
2.41
1.09
8.6
3.8
—
—
—
0
0
54
426
1.34
1.07
1.9
1.7
459.87
441.75
pmol/l
0.18
47
356
29
207
1.45
1.02
3.8
4.3
14.79
58.37
ug/l
0.58
21
177
26
182
1.48
1.01
6.3
2.3
7.31
5.35
ug/l
0.34
21
163
5
23
2.20
0.98
1.0
1.5
—
—
—
0
0
5
23
2.20
0.98
1.0
1.5
—
—
—
0
0
5
23
2.20
0.98
1.0
1.5
—
—
—
0
0
5
23
2.20
0.98
1.0
1.5
—
—
—
0
0
5
23
2.20
0.98
1.0
1.5
—
—
—
0
0
6
28
2.17
0.92
1.0
1.1
—
—
—
0
0
10
165
0.59
0.85
1.8
2.0
—
—
—
0
0
138
1259
1.21
0.77
3.8
3.0
63.76
49.24
u/l
1.07
130
1181
17
116
1.50
0.76
1.8
1.6
—
—
—
0
0
5
24
2.10
0.75
1.0
1.5
—
—
—
0
0
60
505
1.24
0.74
1.7
1.7
1.72
1.36
mmol/l
1.17
54
421
5
25
2.02
0.73
1.0
1.4
—
—
—
0
0
29
369
0.76
0.68
2.3
3.0
0.58
0.75
ug/l
1.21
18
239
178
1880
0.83
0.68
4.9
4.5
5.94
6.01
mmol/l
0.29
162
1688
12
178
0.66
0.67
1.8
2.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
0
22
0.00
0.59
0.0
2.7
—
87.30
—
0
22
29
234
1.27
0.52
3.9
4.4
35.71
31.40
%
1.02
21
141
16
119
1.37
0.49
1.3
1.2
38.96
165.05
iu/ml
—
7
43
5
31
1.62
0.43
1.4
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
512.10
—
0
10
0
19
0.00
0.39
0.0
1.0
—
39.43
—
0
10
29
249
1.19
0.32
10.4
7.2
—
—
—
0
0
7
56
1.26
0.29
2.0
1.4
—
—
—
0
0
210
2146
0.89
0.28
49.3
21.1
38.93
40.03
%
2.11
198
2016
5
74
0.67
0.26
1.4
1.6
—
—
—
0
0
186
1809
1.10
0.25
7.4
5.8
40.97
40.25
mmol/mol
0.39
174
1668
6
85
0.70
0.24
1.8
1.9
—
—
—
0
0
47
510
0.90
0.22
4.2
4.4
23.01
21.95
%
0.13
21
242
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
367.60
—
0
5
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
6
50
1.20
0.20
1.0
1.1
—
4.07
—
0
6
28
252
1.12
0.18
1.5
1.5
—
—
—
0
0
192
1950
0.94
0.13
5.3
5.0
2.53
2.72
mmol/l
2.10
177
1779
12
138
0.86
0.13
2.8
2.2
11.42
14.07
nmol/l
0.66
12
130
149
1458
1.05
0.12
4.1
3.9
15.20
14.79
pmol/l
1.15
132
1296
186
1887
0.95
0.11
5.0
4.4
1.38
1.45
mmol/l
1.67
170
1724
5
45
1.11
0.10
1.2
1.4
—
—
—
0
0
187
1847
1.04
0.09
29.2
13.6
74.70
79.21
ml/min/173m2
1.48
162
1505
5
64
0.78
0.08
2.6
1.5
—
—
—
0
0
5
64
0.78
0.08
1.4
1.8
—
—
—
0
0
9
86
1.05
0.07
1.0
1.0
—
—
—
0
0
9
101
0.89
0.06
1.3
2.9
4.43
4.30
pmol/l
—
9
87
188
1895
0.97
0.05
4.9
4.5
4.39
4.62
mmol/l
2.05
174
1743
182
1832
0.98
0.03
4.5
4.0
1.34
1.29
mmol/l
0.44
165
1659
115
1158
0.99
0.01
3.5
3.0
—
—
—
0
0
62
625
0.99
0.00
4.0
5.0
1.96
2.37
ug/l
0.46
57
558
178
1775
1.01
0.00
4.8
4.7
2.12
1.92
mu/l
1.08
167
1587
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
1.18
—
0
5
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
77.20
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
4.2
—
61.70
—
0
6
0
6
0.00
-0.00
0.0
1.7
—
37.50
—
0
6
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
9
95
0.95
-0.00
1.0
1.3
—
—
—
0
0
6
60
1.00
-0.00
1.0
1.2
—
—
—
0
0
6
61
0.98
-0.00
1.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_POLNODOSA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLNODOSA | 2.456 [2.03, 2.97] | < 0.001 |
| Birth year | 1.0 [0.99, 1.01] | 0.939 |
During the follow-up period (1.1.1998 — 31.12.2019), 585 out of 1085 females with M13_POLNODOSA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POLNODOSA | 2.422 [1.81, 3.24] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.042 |
During the follow-up period (1.1.1998 — 31.12.2019), 269 out of 625 males with M13_POLNODOSA died.
Mortality risk
Mortality risk for people of age
years, who have M13_POLNODOSA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.36% | 0.392% |
| 5 | 1.66% | 3.074% |
| 10 | 4.388% | 7.997% |
| 15 | 8.081% | 15.044% |
| 20 | 13.718% | 24.31% |
Relationships between endpoints
↥Index endpoint: M13_POLNODOSA – Polyarteritis nodosa
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data